RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Status:
Recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one
virus responsible for the common cold. Vapendavir prevents the virus from entering cells and
making more infectious copies of itself. A study is being planned to investigate VPV in
patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult
to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in
treating any indication (disease) by the FDA or any other global regulatory agency.
Therefore, VPV is considered investigational, and the study doctor is conducting this
investigational research study. Safety will be monitored throughout the entire study.